Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) Other Non Operating Income (2016 - 2025)

Surgery Partners' Other Non Operating Income history spans 11 years, with the latest figure at -$1.3 million for Q3 2025.

  • For Q3 2025, Other Non Operating Income changed N/A year-over-year to -$1.3 million; the TTM value through Sep 2025 reached -$1.3 million, up 93.69%, while the annual FY2025 figure was -$1.3 million, 74.51% up from the prior year.
  • Other Non Operating Income for Q3 2025 was -$1.3 million at Surgery Partners, up from -$5.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $500000.0 in Q3 2021 and bottomed at -$15.5 million in Q4 2023.
  • The 5-year median for Other Non Operating Income is -$5.1 million (2024), against an average of -$7.3 million.
  • The largest YoY upside for Other Non Operating Income was 4.03% in 2023 against a maximum downside of 4.03% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $500000.0 in 2021, then tumbled by 3080.0% to -$14.9 million in 2022, then dropped by 4.03% to -$15.5 million in 2023, then skyrocketed by 67.1% to -$5.1 million in 2024, then soared by 74.51% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Other Non Operating Income are -$1.3 million (Q3 2025), -$5.1 million (Q2 2024), and -$15.5 million (Q4 2023).